Global Cancer Gene Therapy Market Research and Forecast 2022-2028

Description

List of Tables

Global Cancer Gene Therapy Market Size, Share & Trends Analysis Report by Therapy (Gene Transfer Immunotherapy, Oncolytic Virotherapy, and Gene Induced Immunotherapy), and by End-Users (Hospitals, Research Institutes, and Biotech Companies) Forecast Period (2022-2028)

The global cancer gene therapy market is anticipated to grow at a substantial CAGR of 23.1% during the forecast period. One of the major factors that are fueling the market includes the rising pool of population with cancer patients coupled with an increasing geriatric population base. Globally there is a rise in cancer patients each year. Several initiatives are being launched about gene therapy catering to treating and reducing the number of cancer incidences across the globe. For instance, in October 2021, the National Institutes of Health, the US Food and Drug Administration (US FDA), ten pharmaceutical companies, and five non-profit groups have teamed up to speed up gene therapy development for the 30 million Americans who suffer from a rare disease. Such measures are expected to boost demand for gene therapy, boosting the market growth. Additionally, in October 2019, GammaDelta Therapeutics announced the formation of the spinout company Adaptate Biotherapeutics. Adaptate develops therapeutic antibodies that can modulate the activity of gamma delta T-cells to trigger an immune response to fight cancer.

The global cancer gene therapy market can be segmented based on therapy and end-users. Based on the therapy, the cancer gene therapy market is segmented into gene transfer immunotherapy, oncolytic virotherapy, and gene-induced immunotherapy. The gene-induced immunotherapy is further segmented as delivery of cytokines gene and delivery of tumor antigen gene. Based on end-users, the global cancer gene therapy market is diversified as hospitals, research institutes, and biotech companies. Among the therapy, the immunotherapy segment is expected to hold a considerable share in the global market owing to the rise in advancement of gene-induced immunotherapy research along with various R&D activities.

Geographically the global cancer gene therapy market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Europe is projected to hold a prominent share after North America owing to the presence of a large pool of cancer patients and the aging population. For instance, in January 2020, a group of researchers at Cardiff University discovered a new type of T-cells that have the potential to attack a wide range of cancers, such as leukemia and melanoma. Ervaxx is continuously expanding its repertoire of Dark Antigens. Using these, the company is working on a pipeline of off-the-shelf cancer vaccines and TCR-based therapies.

The major companies serving the global cancer gene therapy market include Amgen Inc., Bluebird Bio, Gilead Sciences, Inc., Novartis AG, Orchard Therapeutics, Sibiono GeneTech Co. Ltd., Spark Therapeutics (Roche AG), and UniQure N.V., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2020, the US FDA accepted and granted priority review to Merck and AstraZeneca's regulatory submission of LYNPARZA (Olaparib) for the treatment of metastatic castration-resistant prostate cancer and deleterious, suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations that have progressed a prior treatment with the hormonal agent.

Research Methodology

The market study of the global cancer gene therapy market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Cancer Gene Therapy Market Research and Analysis by Therapy.

Global Cancer Gene Therapy Market Research and Analysis by End-Users.

The Report Covers

Comprehensive research methodology of the global cancer gene therapy market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global cancer gene therapy market.

Insights about market determinants that are stimulating the global cancer gene therapy market.

Detailed and extensive market segments with the regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Product Code: OMR2018307

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Cancer Gene TherapyMarket
Recovery Scenario of Global Cancer Gene TherapyMarket
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. ByRegion

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. Amgen, Inc.
  - 3.1.1.1. Overview
  - 3.1.1.2. Financial Analysis
  - 3.1.1.3. SWOT Analysis
  - 3.1.1.4. Recent Developments
- 3.1.2. Biogen Inc.
  - 3.1.2.1. Overview
  - 3.1.2.2. Financial Analysis
  - 3.1.2.3. SWOT Analysis
  - 3.1.2.4. Recent Developments
- 3.1.3. Bluebird Bio, Inc.
  - 3.1.3.1. Overview
  - 3.1.3.2. Financial Analysis
  - 3.1.3.3. SWOT Analysis
  - 3.1.3.4. Recent Developments
- 3.1.4. Gilead Sciences, Inc.
  - 3.1.4.1. Overview
  - 3.1.4.2. Financial Analysis
  - 3.1.4.3. SWOT Analysis
  - 3.1.4.4. Recent Developments
- 3.1.5. Novartis AG
  - 3.1.5.1. Overview
  - 3.1.5.2. Financial Analysis
  - 3.1.5.3. SWOT Analysis
  - 3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

4.1. Global Cancer Gene Therapy Market by Therapy
- 4.1.1. Gene Transfer Immunotherapy
- 4.1.2. Oncolytic Virotherapy
- 4.1.3. Gene Induced Immunotherapy
  - 4.1.3.1. Delivery Of Cytokines Gene
  - 4.1.3.2. Delivery Of Tumor Antigen Gene
4.2. Global Cancer Gene Therapy Market by End-Users
- 4.2.1. Hospitals
- 4.2.2. Research Institutes
- 4.2.3. Biotech Companies

5. Regional Analysis

5.1. North America
- 5.1.1. US
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Achilles Therapeutics Ltd.
6.2. Adaptimmune Therapeutics Plc
6.3. American Gene Technologies International Inc.
6.4. Avrobio Inc.
6.5. Beigene, Ltd.
6.6. Bluebird Bio, Inc.
6.7. Celgene Corporation
6.8. Cell Medica Ltd.
6.9. Formula Pharmaceuticals, Inc.
6.10. Genprex, Inc.
6.11. Genvec Inc.
6.12. GlaxosmithklinePLC
6.13. Illumina, Inc.
6.14. Inovio Pharmaceuticals, Inc.
6.15. Jounce Therapeutics, Inc.
6.16. Merck &Co., Inc.
6.17. Morphogenesis, Inc.
6.18. Oxford Biomedica Plc
6.19. Sangamo Therapeutics, Inc.
6.20. Sirion Biotech GmbH
6.21. Spark Therapeutics Inc.
6.22. Synergene Therapeutics, Inc.